

## Notice of a Shareholder webinar “Funding, execution and path forward”

**08 January 2026 – Melbourne Australia:** Neurizon® Therapeutics Limited (ASX: NUZ & NUZOA; OTCQB: NUZTF) ("Neurizon" or "the Company"), a clinical-stage biotech company dedicated to advancing innovative treatments for neurodegenerative diseases, is pleased to advise it will be hosting a shareholder webinar at 1:00pm AEDT (10:00am AWST) on Thursday, 15 January 2026.

During the webinar, CEO and Managing Director, Dr. Michael Thurn and other team members will provide an update on the execution of recent funding initiatives, regulatory developments and pending operational milestones associated with the HEALEY ALS Platform Trial.

The briefing will be followed by a Q&A session. Questions can be submitted now to [enquiries@neurizon.com](mailto:enquiries@neurizon.com), during the registration or in written form during the webinar. Anyone wishing to attend the webinar must register via the link below.

- **Registration:** <https://bit.ly/15012026>
- **Date and time:** 1:00pm AEDT (10:00am AWST) on Thursday, 15 January 2026

For investors that cannot attend the webinar, a recording will be made available via the Company's website.

-ENDS-

This announcement has been authorised for release by Michael Thurn, Managing Director and CEO on behalf of the Board of Neurizon Therapeutics Limited.

For further information, please contact:

**Neurizon Therapeutics**

Lidija Damjanovic  
Marketing & Corporate Affairs  
Email: [lidija@neurizon.com](mailto:lidija@neurizon.com)  
Phone: +61 (0) 425 700 504

**Australia Investor Relations**

Henry Jordan  
Six Degrees Investor Relations  
Email: [henry.jordan@sdir.com.au](mailto:henry.jordan@sdir.com.au)  
Phone: +61 (0) 431 271 538

**U.S. Investor Relations**

Matthew Selinger  
Integrus Communications  
Email: [mselinger@integcom.us](mailto:mselinger@integcom.us)  
Phone: +1 415-572-8152

### About Neurizon Therapeutics Limited

Neurizon Therapeutics Limited (ASX: NUZ) is a clinical-stage biotechnology company dedicated to advancing treatments for neurodegenerative diseases. Neurizon is developing its lead drug candidate, NUZ-001, for the treatment of ALS, which is the most common form of motor neurone disease. Neurizon's strategy is to accelerate access to effective ALS treatments for patients while exploring the potential of NUZ-001 for broader neurodegenerative applications. Through international collaborations and rigorous clinical programs, Neurizon is dedicated to creating new horizons for patients and families impacted by complex neural disorders. NUZ-001 is an investigational product and is not approved for commercial use in any jurisdiction.

### Neurizon Investor Hub

We encourage you to utilise our Investor Hub for any enquiries regarding this announcement or other aspects concerning Neurizon.

This platform offers an opportunity to submit questions, share comments, and view video summaries of key announcements.

To access Neurizon Investor Hub please scan the QR code or visit  
<https://investorhub.neurizon.com>



Neurizon® is a registered trademark of Neurizon Therapeutics Limited.